6 stories mentioning SHE:002773
Every FINWIRES story that references SHE:002773, newest first.
Chengdu Kanghong Pharmaceutical (SHE:002773) purchased 1.7 billion yuan of structured deposit products from Bank of China (HKG:3988, SHA:601988).The deposit product has a 204-day term expiring Dec. 30, according to a Wednesday bourse filing in Shenzhen.
Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotech, purchased a wealth management product for 1.70 billion yuan, according to a Shenzhen bourse filing on Wednesday.The wealth management product is a renminbi-denominated structured deposit from Bank of China (SHA:601988, HKG:3988), with a term of 204 days.The product's annualized return is 0.60% if its linked indicator reaches or exceeds the observation level, but the annualized return would be at 1.75% if the linked indicated remains below the observation level throughout the observation period.
Chengdu Kanghong Pharmaceutical (SHE:002773) purchased 200 million yuan of structured deposit products from Bank of China (HKG:3988, SHA:601988), according to a Tuesday filing with the Shenzhen bourse.The wealth management product has a term of 207 days, expiring on Dec. 25, 2026.
Chengdu Kanghong Pharmaceutical (SHE:002773) obtained drug registration from China's medical products regulator for 2- and 4-milligram dosages of perapanel tablets.The drug is used to treat partial-onset and primary generalized tonic-clonic seizures, according to a Friday fling with the Shenzhen bourse.Shares of the pharmaceutical company were down 1% in recent trade.
Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotechnology, received approval from China's National Medical Products Administration for the clinical trial of KH812 injection, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for neovascular (wet) age-related macular degeneration.
Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Hongji Biotechnology, said the U.S. Food and Drug Administration authorized the clinical trials of KHN921 injection in the U.S., according to a Shenzhen bourse filing on Monday.The drug will be tested as a treatment for hypertrophic cardiomyopathy.The pharmaceutical company's shares rose 2% during the afternoon trade.